1-7 of 7
David Kipp
Close
Sort by
Journal Articles

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Andrew H Wei, Harry J Iland, John Reynolds, Sun Loo, Chong Chyn Chua, David Westerman, Ing S Tiong, Adam Ivey, Piers Blombery, Natasha S Anstee, Rachel M Koldej, David J. Curtis, David Kipp, David Ritchie, David M Ross, Amanda Souza, Jenny Collins, Ashish Bajel, Carolyn Grove, Paula Marlton, Andrew W Roberts, Naveen Pemmaraju, Keyur P. Patel, Sanam Loghavi, Marina Konopleva, Naval Daver, Courtney D. DiNardo
Journal: Blood
Blood (2022) 140 (Supplement 1): 3341–3343.
https://doi.org/10.1182/blood-2022-167837
Published: 2022
Journal Articles

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2350.
https://doi.org/10.1182/blood-2021-154247
Published: 2021
Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, Naranie Shanmuganathan, MBBS FRACP FRCPA, Ann Christine Solterbeck, BSc(Hons) MSc PhDAstat, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD FFSc (RCPA), Nicholas Viiala, MBBS FRACP FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K Mills, FRACP, FRCPA, MBBS, Jake Shortt, MBBS FRACP FRCPA PhD, Campbell Tiley, MBBS, FRACP, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, Ilona Cunningham, MBBS FRACP FRCPA, John Kwan, MBBS,FRACP,FRCPA, Richard Eek, MBChB MMED, FCP, FRACP., Howard Mutsando, MBChB FRACP FRCPA, Ken-Soon Tan, MMed FRACP MRCP(UK) MA MBBChir BA(Hons), Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 4150.
https://doi.org/10.1182/blood-2019-127619
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Anne Harrup, MD, David M Ross, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, Anthony P Schwarer, MD MBBS(Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP, FRCPA, Nicholas Viiala, MBBS, FRACP, FRCPA, Robert Weinkove, MA, MBBS, PhD, FRCPath, FRACP, Agnes S. M. Yong, MD, PhD, Deborah L White, PhD, Susan Branford, PhD, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2018) 132 (Supplement 1): 459.
https://doi.org/10.1182/blood-2018-99-110569
Published: 2018
Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, MBBS FRACP FRCPA, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, MBBS PhDFRACP FRCPA, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Harrap, MBBS FRACP FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MA, MBBS, PhD FRCPath, FRACP, Agnes S. M. Yong, MDPhD, Deborah L White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 2898.
https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898
Published: 2017
Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD
Journal: Blood
Blood (2013) 122 (21): 2129.
https://doi.org/10.1182/blood.V122.21.2129.2129
Published: 2013